Loading…
Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.
Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.
Sells to producers of chickens, pigs and cattle through feed companies and distributors, with medicated feed additives, which prevent disease in herds, the largest line, and poultry the largest customer group. The Bendheim family keeps control through a separate class of shares.
Moat: narrow (regulatory licence, scale, distribution). Registered animal-drug approvals and an established livestock distribution network limit new entrants.
Headquarters: Teaneck, New Jersey, US · Founded: 1954 · Employees: 2,605
Size Phibro Animal Health (PAHC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 2068th largest of 3,117 United States companies the cockpit tracks. Shares closed at $32.96 on 6 Nov 2026.
Performance Over six months the shares fell 17.6%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 17.1% over the last twelve months (peer median +16.1%); the operating margin is 13.2% (peer median 1.8%).
Valuation It trades at 9.1× forward earnings against a peer median of 19.2× (2nd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.1 points above its cost of capital (6.4% WACC).
Short interest Short interest is 4.9% of the free float (15 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $1.52B | $1.52B | $1.30B | $1.02B | $978M |
| Revenue growth | — | +17% | +27% | +4% | — |
| Gross profit | $510M | $510M | $391M | $312M | $299M |
| EBITDA | $252M | $252M | $167M | $98.6M | $114M |
| Net income | $99.7M | $99.7M | $48.3M | $2.42M | $32.6M |
| Free cash flow | $9.87M | $9.87M | $41.8M | $46.4M | -$38.5M |
| Capital expenditure | $59.1M | $59.1M | $38.3M | $41.2M | $51.8M |
| Total debt | $789M | $789M | $762M | $525M | $510M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Phibro Animal Health PAHC | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
| Elanco Animal Health ELAN | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PAHC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.9% | -6.4% | 8th lowest of 21 |
| 6-month return | -17.6% | -10.9% | 8th lowest of 21 |
| Distance from 52-week high | -45.1% | -36.2% | 7th lowest of 21 |
| Revenue growth (TTM) | +17.1% | +16.1% | 9th highest of 17 |
| Operating margin | 13.2% | 1.8% | 4th highest of 17 |
| Forward P/E | 9.1× | 19.2× | 2nd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -7.4% | 2.1% | 2nd least demanding of 7 |
| Growth delivered (Del g) | +12.7% | +8.9% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | -20.1 pp | -7.3 pp | 2nd least demanding of 7 |
| ROIC minus cost of capital | +8.1 pp | -5.2 pp | highest of 18 |
| EV / EBITDA | 8.1× | n/a | — |
| Net debt / EBITDA | 2.8× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |